Different Efficacy of Burosumab on Physical Performance and Serum Phosphate in Adult Patients with X-Linked Hyphophosphatemic Rickets during the First Six-Month of Treatment

Burosumab is a monoclonal anti-FGF23 antibody used to treat patients with X-linked hypophosphatemic rickets (XLH). Its effect on serum phosphate and physical performance was compared in patients during a 6-month treatment with burosumab. Eight adult patients with XHL were treated with burosumab (1 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcidiacono, Teresa, Foligno, Nadia E., Brioni, Elena, Bologna, Arianna, Weber, Giovanna, Mora, Stefano, Pitea, Marco, Vitale, Corrado, Vezzoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143203/
https://www.ncbi.nlm.nih.gov/pubmed/37109242
http://dx.doi.org/10.3390/jcm12082906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143203/
https://www.ncbi.nlm.nih.gov/pubmed/37109242
http://dx.doi.org/10.3390/jcm12082906

Ejemplares similares